NCT06994299撤回2 期
A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Safety, as measured by the number of Grade 3+ CTCAE treatment related toxicity rates within three months from start of treatment
研究概览
简要总结
This is an early-phase study testing a new combination treatment for cancer. participants will receive a type of radiation therapy called MRI-guided or CT-guided radiotherapy, depending on which imaging method is safe for them. The radiation will be given in three sessions, each delivering a moderate dose (8 Gray), focused only on the visible tumor.
At the same time, participants will receive immunotherapy, which is a treatment that helps the immune system fight cancer. This includes one dose of a drug called Tremelimumab and regular doses of another drug called Durvalumab, given every four weeks.
The goal of this study is to see if this combination is safe and shows signs of helping patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act in the US, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
- •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Age ≥ 18 years
- •ECOG performance status 0-1
- •Life expectancy for at least 12 weeks
- •Body weight >30kg
- •LIRADS 5 or biopsy confirmed hepatocellular carcinoma (HCC)
- •Patients with histologically confirmed HCC (Documentation of original biopsy for diagnosis is acceptable if tumor tissue is unavailable) or clinical diagnosis by AASLD criteria in cirrhotic subjects is required (presence of arterial hypervascularity with venous washout).
- •For subjects without cirrhosis, histological confirmation is mandatory.
- •Patient's must have resectable HCC. The determination of resectability status will ultimately lie in the clinical judgment of the surgical oncologist, medical oncologist, and radiation oncologist involved in the care of the patient.
- •Patient must have measurable disease defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) and measures ≥ 15 mm with conventional techniques or
- •o ≥ 10 mm with more sensitive techniques such as MRI or spiral CT (Computed Tomography) scan.
- •Patient can have prior treatment for HCC including prior surgery, radiation therapy, local-regional therapy (ablation or arterial directed therapies), and systemic therapy including sorafenib or chemotherapy (but not anti-PD-1 or anti-CTLA-4 therapy).
- •Patients with grade 2+ neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
- •Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
- •No evidence of distant metastases
- •No infections requiring systemic antibiotic treatment
- •Hgb >9.0 gm/dL, PLT > 100,000/mm3, total bilirubin ≤ 1.5x upper limit of normal
- •Exclusion Criteria
- •Any other malignancy from which the patient has been disease-free for less than 5 years, except for non- melanoma skin cancer, or in situ carcinoma of any site.
- •Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
- •Patients who have organ allografts.
- •Patients who have had a major surgical procedure, open biopsy, or significant traumatic injury with poorly healed wound within 6 weeks prior to first dose of study drug; or anticipation of need for major surgical procedure during the study (other than defined by protocol); fine needle aspirations or core biopsies within 7 days prior to first dose of study drug. NOTE: Patients will be allowed to start cycle 1 day 1 therapy after 24 hours from pre-treatment biopsy.
- •Autoimmune disease: Patients with a history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis) are excluded from this study as are patients with a history of autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's granulomatosis]).
- •Known history of testing positive for human immunodeficiency virus (HIV) (positive HIV 1 /2 antibodies) or known acquired immunodeficiency syndrome (AIDS).
- •Active tuberculosis infection (clinical evaluation that may include history, physical examination, and radiographic findings or tuberculosis testing in line with local practive).
- •Any underlying medical condition, which, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of adverse events, such as a condition associated with frequent diarrhea.
- •Patients who have had a history of acute diverticulitis, abdominal fistula, gastrointestinal perforation, intra- abdominal abscess, GI obstruction, abdominal carcinomatosis which are known risks factors for bowel perforation, should be excluded from the study.Patients who have a primary brain tumor (excluding meningiomas and other benign lesions), any brain metastases, leptomeningeal disease, seizure disorders not controlled with standard medical therapy, or history of stroke within the past year.
- •History of serious systemic disease, including myocardial infarction or unstable angina within the last 12 months, history of hypertensive crisis or hypertensive encephalopathy, uncontrolled hypertension (blood pressure of >140/90 mmHg) at the time of enrollment, New York Heart Association (NYHA) Grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), significant vascular disease or symptomatic peripheral vascular disease.
- •Patients who have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.
排除标准
- 未提供
研究组 & 干预措施
Stereotactic Body Radiotherapy for HCC
Experimental
Hypofractionated radiotherapy - 8Gy x3 fractions (week 0) Tremelimumab - single dose of 300 mg IV (week 0). Durvalumab - 1500 mg IV every 4-weeks (weeks 0-3) prior to hepatic resection Surgery - hepatic resection (week 7)
干预措施: Radiation Therapy (Radiation)
Stereotactic Body Radiotherapy for HCC
Experimental
Hypofractionated radiotherapy - 8Gy x3 fractions (week 0) Tremelimumab - single dose of 300 mg IV (week 0). Durvalumab - 1500 mg IV every 4-weeks (weeks 0-3) prior to hepatic resection Surgery - hepatic resection (week 7)
干预措施: Tremelimumab (Drug)
Stereotactic Body Radiotherapy for HCC
Experimental
Hypofractionated radiotherapy - 8Gy x3 fractions (week 0) Tremelimumab - single dose of 300 mg IV (week 0). Durvalumab - 1500 mg IV every 4-weeks (weeks 0-3) prior to hepatic resection Surgery - hepatic resection (week 7)
干预措施: Durvalumab (Drug)
Stereotactic Body Radiotherapy for HCC
Experimental
Hypofractionated radiotherapy - 8Gy x3 fractions (week 0) Tremelimumab - single dose of 300 mg IV (week 0). Durvalumab - 1500 mg IV every 4-weeks (weeks 0-3) prior to hepatic resection Surgery - hepatic resection (week 7)
干预措施: Surgery (Procedure)
结局指标
主要结局
Safety, as measured by the number of Grade 3+ CTCAE treatment related toxicity rates within three months from start of treatment
时间窗: Within 3 months from start of treatment
Efficacy, as measured by major pathologic response rates determined from resected surgical specimens
时间窗: Week 7
次要结局
- Feasibility as measured by the recruitment timeline(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ AdenocarcinomaGastric CancerEsophageal CancerNCT00737438Memorial Sloan Kettering Cancer Center22
已完成
1 期
Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) PatientsColon CancerNCT02891538The University of Texas Health Science Center at San Antonio51
已完成
1 期
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal CancerAdenocarcinoma of the RectumMucinous Adenocarcinoma of the RectumSignet Ring Adenocarcinoma of the RectumStage IIA Rectal CancerStage IIB Rectal CancerStage IIC Rectal CancerStage IIIA Rectal CancerStage IIIB Rectal CancerStage IIIC Rectal CancerNCT00003799National Cancer Institute (NCI)20
已完成
2 期
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)Facial Cutaneous Squamous Cell Carcinoma in SituNCT06159842The Center for Clinical and Cosmetic Research32
招募中
2 期
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)Cutaneous Squamous Cell CarcinomaNCT06577311The Center for Clinical and Cosmetic Research20